- In Oral Maintenance Therapy in AML, Do All Roads Lead to the Epigenome?
Sunday, November 1st, 2020
Maintenance therapy to reduce relapse of acute myeloid leukemia (AML) and prolong overall survival (OS) has been explored since the 1960s.1 Chemotherapeutic and immunologic approaches have all failed to improve OS. Only one intervention has been approved for this indication (in 2008, and in Europe only): the rarely used combination of histamine dichloride and interleukin-2. [...]